---
document_datetime: 2025-05-14 13:24:30
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/atazanavir-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: atazanavir-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.137914
conversion_datetime: 2025-12-27 21:26:57.246263
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Atazanavir Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                       |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 14/05/2025                          |                                             | SmPC,                            | To update sections 4.3 and 4.4 of the SmPC in |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000268126   | Labelling and PL   | order to clarify the contraindication for the co- administration of atazanavir with strong inducers of CYP3A4, based on the results from study AI424082.   |
|---------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000255132   | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted   | 27/02/2025   | N/A   | Annex II and PL   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------|

<div style=\"page-break-after: always\"></div>

|                                                         | B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted   |            |            |                        |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000178550 | - Transfer of a marketing authorisation - Accepted Transfer of Marketing Authorisation from Mylan Pharmaceuticals Limited to Viatris Limited.                                                                                                                                                                                                                                                                                                                       | 31/05/2024 | 29/07/2024 | SmPC, Labelling and PL |
| Variation type IA_IN / EMA/VR/0000174634                | A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted                                                                                                                                                                                                                                                                                                                                                    | 18/04/2024 | 13/06/2024 | SmPC, Labelling and PL |